4 terminated. 4 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Terminated 4 |
| Phase 2 | 2 | Terminated 2 |
Follow parsaclisib: new trials by email Literature Review of parsaclisib trials Research Report on parsaclisib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma Parsaclisib, Chidamide - Peripheral T-Cell Lymphoma | Phase 1 | Terminated | Henan Cancer Hospital | 12 | 2022-02-20 | 2025-12-02 |
| A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) tafasitamab, parsaclisib - Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma | Phase 1 / Phase 2 | Terminated | Incyte Corporation | 54 | 2021-09-16 | 2026-02-04 |
| Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid Tumors Itacitinib, Epacadostat, INCB050465 - Solid Tumors | Phase 1 | Terminated | Incyte Corporation | 142 | 2015-11-01 | 2019-09-25 |
| An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies INCB052793, gemcitabine, nab-paclitaxel - Solid Tumors, Advanced Malignancies | Phase 1 / Phase 2 | Terminated | Incyte Corporation | 83 | 2014-09-10 | 2020-04-17 |
Leukemia (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, Non-Hodgkin (1) · Lymphoma, T-Cell, Peripheral (1) · Neoplasm Metastasis (1) · Recurrence (1)
Incyte Corporation (3) · Henan Cancer Hospital (1)
United States (3) · Austria (1) · Belgium (1) · China (1) · France (1) · Germany (1) · Italy (1) · Spain (1)
Ekaterine Asatiani, M.D. (1) · Lance Leopold, MD (1) · Oliver Manzke, MD (1) · Yanyan Liu, M.D. Ph.D (1)